   |
Search abstracts
Jochen Zisowsky, Noelia Nebot, Giulia Lestini, Günter Heimann | Simulation Study on a Method for PK-QT Analyses When Several Active Compounds or Metabolites Are Present | 2017 | 25-1-2017 10:42:56 | Poster: Drug/Disease modelling - Safety |
The minimal continuous-time Markov pharmacometric model | 2017 | 1-2-2017 9:53:07 | Poster: Methodology - New Modelling Approaches | |
Systems pharmacology modelling of alternative pathway of complement activation | 2017 | 2-2-2017 13:47:59 | Poster: Drug/Disease modelling - Other topics | |
Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in human | 2017 | 3-2-2017 17:28:02 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Use of distributed delay in PML | 2017 | 7-2-2017 22:14:56 | Poster: Methodology - New Modelling Approaches | |
Population pharmacokinetic analysis of perioperative factor IX dosing in hemophilia B | 2017 | 8-2-2017 9:23:47 | Poster: Drug/Disease modelling - Other topics | |
Physiologically based pharmacokinetic model (PBPK) for the halofantrine cardiac effect prediction – proof of concept study towards the system for the antimalarial drugs cardiac safety assessment. | 2017 | 8-2-2017 11:53:47 | Poster: Drug/Disease modelling - Safety | |
Application of modelling and simulation (M&S) methods within the context of a paediatric-use marketing authorisation (PUMA) application | 2017 | 9-2-2017 13:31:57 | Poster: Drug/Disease modelling - Paediatrics | |
New population pharmacokinetic model that predicts the individual starting dose of tacrolimus following pediatric renal transplantation | 2017 | 9-2-2017 14:50:01 | Poster: Drug/Disease modelling - Paediatrics | |
Olusola Olafuyi(1), Michael Coleman(2) and Raj K. S. Badhan(1,2) | The Use of Physiologically Based Pharmacokinetic Modelling in Assessing Drug–drug Interactions Associated with Antimalarial Treatment in Paediatrics Co-infected with Tuberculosis: A Case Study with Lumefantrine and Rifampicin. | 2017 | 9-2-2017 17:41:30 | Poster: Drug/Disease modelling - Paediatrics |
Daniel Moj (1), Hannah Britz (1), Gerlinde Egerer (2), Walter Emil Haefeli (3) and Thorsten Lehr (1) | Application of a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat to improve dosing regimens in adults | 2017 | 10-2-2017 13:25:25 | Poster: Drug/Disease modelling - Absorption & PBPK |
Dexmedetomidine pharmacodynamics in healthy volunteers: Striking a balance between the hypnotic and sedative properties and the haemodynamic side effects. | 2017 | 10-2-2017 14:31:59 | Poster: Drug/Disease modelling - Other topics | |
Jacob Leander (1), Sergey Aksenov (2), Jesse Hall (3), Ulf Eriksson (1) | Pharmacodynamic modeling of uric acid turnover and the effect of Verinurad (RDEA3170), a novel selective uric acid reabsorption inhibitor for the treatment of gout and asymptomatic hyperuricemia | 2017 | 10-2-2017 14:53:26 | Poster: Drug/Disease modelling - Other topics |
A Mechanistic Pharmacokinetic Approach to the Development of Predictive Models in HIV-malaria co-infection. | 2017 | 10-2-2017 15:48:36 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Khaled Abduljalil (1), Trevor N. Johnson (1), Masoud Jamei (1) | Application of Physiologically-Based Pharmacokinetic model To Predict Tramadol Concentration in human Milk | 2017 | 13-2-2017 10:27:25 | Poster: Drug/Disease modelling - Absorption & PBPK |
How many bits of information did my study provide? Examining Kullback-Leibler divergence, standard errors and shrinkage | 2017 | 13-2-2017 15:59:14 | Poster: Methodology - Model Evaluation | |
Increase in glucose as pharmacodynamic biomarker following administration of the PI3K/mTOR inhibitor LY3023414: quantitative description using modelling. | 2017 | 13-2-2017 22:05:27 | Poster: Drug/Disease modelling - Other topics | |
Serge Guzy(1), Nathan Teuscher(2), Micha Levi(3), Steve Gorman(4) and Frank Schneider(5) | Population Pharmacokinetic of L-DOPA and its main metabolites: Use of the Phoenix based QRPEM algorithm | 2017 | 14-2-2017 13:03:53 | Poster: Drug/Disease modelling - Other topics |
Population Pharmacokinetic-Pharmacodynamic modeling of furosemide for anti-hypertensive effect | 2017 | 14-2-2017 13:37:29 | Poster: Drug/Disease modelling - Absorption & PBPK | |
David James, Jennifer Ng, Jiawei Wei, and Marc Vandemeulebroecke | Multi-state modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to inform drug development | 2017 | 14-2-2017 15:28:49 | Poster: Drug/Disease modelling - Oncology |
Exploring the impact of study design on unperturbed tumour growth inhibition modelling | 2017 | 15-2-2017 11:14:28 | Poster: Methodology - Model Evaluation | |
Ben K Margetts (1,2,3), Judith Breuer (2,3), Nigel Klein (2,3), and Joseph F Standing (1,2,3) | Modelling Cytomegalovirus Growth Kinetics in Immunocompromised Children | 2017 | 15-2-2017 12:25:57 | Poster: Drug/Disease modelling - Infection |
The 6 biggest pharmacometrics modelling mistakes! | 2017 | 15-2-2017 15:52:08 | Oral: Methodology - New Modelling Approaches | |
One Health: Translational and Reverse Translational Modeling of Inflammatory Bowel Disease using an advanced Boolean Network | 2017 | 15-2-2017 16:21:32 | Poster: Drug/Disease modelling - Other topics | |
Use of population PK/PD modeling to support the regulatory approval of canakinumab as first biologic treatment in patients with periodic fever syndromes | 2017 | 17-2-2017 11:29:43 | Poster: Methodology - Model Evaluation | |
Carlos Perez-Ruixo (1), Bart Remmerie (1), Juan Jose Perez-Ruixo (1), and An Vermeulen (1) | Identifying lack of adherence to antipsychotic treatment using plasma concentrations measurements | 2017 | 20-2-2017 9:28:22 | Poster: Drug/Disease modelling - CNS |
nlmixr: an open-source package for pharmacometric modelling in R | 2017 | 20-2-2017 13:00:13 | Poster: Methodology - Estimation Methods | |
Modeling viral kinetics predicts a rapid establishment of the cytotoxic immune response targeting distinct infected cell compartments in SIV controller macaques (ANRS SIC study) | 2017 | 20-2-2017 13:37:11 | Poster: Drug/Disease modelling - Infection | |
Rikard Nordgren (1), Chunli Chen (1), Ulrika S H Simonsson (1) and Sebastian G Wicha (1) | Calling C functions from NONMEM | 2017 | 20-2-2017 14:42:30 | Poster: Methodology - Other topics |
Baneyx G. (1), Combes F-P. (2), Huang P-H. (4) and Elmeliegy M. (3) | Population pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma. | 2017 | 20-2-2017 16:55:23 | Poster: Drug/Disease modelling - Oncology |
Didier Renard (1), Bruno Bieth (1), Guido Junge (2), Antonio Speziale (2), Karine Lheritier (3) | Label extension for canakinumab in Adult Onset Still’s Disease (AOSD) – Extrapolation from pediatrics to adults | 2017 | 20-2-2017 18:55:38 | Poster: Drug/Disease modelling - Paediatrics |
Physiologically-Based Pharmacokinetic (PBPK) Modeling of the CYP2C8 Substrate Pioglitazone | 2017 | 21-2-2017 9:45:28 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Corinna Maier (1,2), Carolin Loos (1,2), Jan Hasenauer (1,2) | Robust parameter estimation for dynamical systems from outlier-corrupted data | 2017 | 21-2-2017 11:27:33 | Poster: Methodology - Estimation Methods |
Ahmed Nader (1), Ben Kluender (2), Colleen Wegzyn (1), Nisha V Kwatra (1), Nael M Mostafa (1) | Pharmacokinetic and Exposure-Response Analyses for Extrapolation of Efficacy of Adalimumab in Adolescent Patients with Hidradenitis Suppurativa | 2017 | 21-2-2017 11:42:40 | Poster: Drug/Disease modelling - Paediatrics |
Clinical trial simulations to optimize dose finding studies in paediatric oncology | 2017 | 21-2-2017 11:46:37 | Poster: Methodology - Study Design | |
Predicting human foetal exposure using physiologically based pharmacokinetic models | 2017 | 21-2-2017 11:47:59 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Joint modeling of time-varying exposure data and progression-free survival in elotuzumab-treated patients with relapsed/refractory multiple myeloma | 2017 | 21-2-2017 16:11:31 | Poster: Drug/Disease modelling - Other topics | |
Population pharmacokinetics and pharmacodynamics of GSK525762 in patients with solid tumors | 2017 | 21-2-2017 16:26:28 | Poster: Drug/Disease modelling - Oncology | |
Evaluation of a minimal WB-PBPK platform supporting different routes of administration | 2017 | 21-2-2017 17:01:33 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Discrepancy between in vitro potency and in vivo efficacy in human - Implications in PK-PD modeling | 2017 | 22-2-2017 2:45:32 | Poster: Drug/Disease modelling - Other topics | |
Population pharmacokinetics of the sustained-release granule formulation of valproic acid in epileptic children | 2017 | 22-2-2017 9:46:03 | Poster: Drug/Disease modelling - Paediatrics | |
A Bayesian PK/PD model for synergy; a case study | 2017 | 22-2-2017 14:56:03 | Poster: Methodology - New Modelling Approaches | |
Population PK analysis of Sym004 and the influence of variations in base model structure on covariate model building | 2017 | 22-2-2017 17:06:32 | Poster: Methodology - Covariate/Variability Models | |
Joint modeling of moxifloxacin pharmacokinetics and fecal microbiota disruption in healthy volunteers | 2017 | 22-2-2017 21:49:56 | Poster: Drug/Disease modelling - Infection | |
Satoshi Shoji (1), Scott Marshall (2), Rujia Xie (2), and Rosalin Arends (3) | Slow drug-target complex kinetics and first dose overestimation of free target suppression in target-mediated drug disposition (TMDD) approximation models: An evaluation for tanezumab a NGF antibody for treatment of pain | 2017 | 23-2-2017 1:32:45 | Poster: Drug/Disease modelling - Other topics |
Exposure-response analysis of vilaprisan describing uterine fibroid size by population PK/PD modelling | 2017 | 23-2-2017 10:03:06 | Poster: Drug/Disease modelling - Other topics | |
Mathematical modeling of glucose, insulin and c-peptide during the OGTT in pre-diabetic subjects: A DIRECT study | 2017 | 23-2-2017 10:27:30 | Poster: Drug/Disease modelling - Endocrine | |
Population pharmacokinetics of PF-04447943 in healthy volunteers (HV), adult patients with Alzheimer's disease (AD) and patients with Sickle Cell Disease (SCD) | 2017 | 23-2-2017 10:51:54 | Poster: Drug/Disease modelling - Other topics | |
Konstantina Soulele (1), Panos Macheras (1,2), Vangelis Karalis (1) | Population pharmacokinetic analysis of inhaled budesonide in asthma patients | 2017 | 23-2-2017 10:52:57 | Poster: Drug/Disease modelling - Absorption & PBPK |
Investigating the PK/PD relationship of a new pro-apoptotic drug through tumor growth inhibition modelling in NUDE rats | 2017 | 23-2-2017 11:17:08 | Poster: Drug/Disease modelling - Oncology | |
Monia Guidi (1) (2), Alena Simalatsar (1) (3), Sandro Carrara (4), Thierry Buclin (1) | Adequacy of open-loop Target Controlled Infusion devices during anesthesia | 2017 | 23-2-2017 11:22:29 | Poster: Drug/Disease modelling - CNS |
Population pharmacokinetic model for intravenous tocilizumab in rheumatoid arthritis | 2017 | 23-2-2017 13:04:39 | Poster: Drug/Disease modelling - Other topics | |
Bayesian Pharmacokinetic Extrapolation from Dense Adult to Sparse Pediatric Data | 2017 | 23-2-2017 13:55:48 | Poster: Drug/Disease modelling - Paediatrics | |
Population pharmacodynamic model of bronchodilator response to salbutamol in wheezy preschool children | 2017 | 23-2-2017 14:41:43 | Poster: Drug/Disease modelling - Paediatrics | |
Distinguishing between first-pass and systemic CYP3A-mediated metabolism of midazolam in preterm neonates using physiologically-based pharmacokinetic modelling | 2017 | 23-2-2017 15:21:11 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Nina Scherer (1), Christiane Dings (1), Jan Freijer (2), Valerie Nock (2), Thorsten Lehr (1) | A population pharmacokinetic (PK) model of metformin regarding immediate and extended release formulations under fasted and fed conditions | 2017 | 23-2-2017 15:26:36 | Poster: Drug/Disease modelling - Endocrine |
Sabine Stübler (1,2), Charlotte Kloft (3), Wilhelm Huisinga (4) | Towards a systems biology model for inflammatory bowel disease | 2017 | 23-2-2017 15:27:42 | Poster: Drug/Disease modelling - Other topics |
Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis | 2017 | 23-2-2017 15:39:42 | Poster: Drug/Disease modelling - Other topics | |
Simulation of pharmacokinetics of amitriptyline and nortriptyline and their common effect on human cardiac electrophysiology in healthy population | 2017 | 23-2-2017 15:50:54 | Poster: Drug/Disease modelling - Safety | |
The Pmetrics Population Modeling and Monte Carlo Simulation, and BestDose Clinical, Software | 2017 | 23-2-2017 16:10:30 | Software Demonstration | |
Population pharmacokinetics and pharmacodynamics analysis of hydroxyurea, in adult patients with sickle cell anemia (SCA), and evaluation of disease markers | 2017 | 23-2-2017 16:20:21 | Poster: Drug/Disease modelling - Other topics | |
Modelling of rituximab clearance reduction due to ibrutinib co-administration | 2017 | 23-2-2017 16:50:00 | Poster: Drug/Disease modelling - Oncology | |
Pavel Balazki (1, 2), Verena Woerle (3), Stephan Schaller (4), Thomas Eissing(2), Thorsten Lehr (1) | Physiologically-based Pharmacokinetics/Pharmacodynamics model of Dapagliflozin, an oral SGLT2 inhibitor | 2017 | 24-2-2017 9:01:18 | Poster: Drug/Disease modelling - Absorption & PBPK |
Rikard Nordgren, Andrew C. Hooker, Kajsa Harling, Svetlana Freiberga and Mats O. Karlsson | PsN and Xpose | 2017 | 24-2-2017 9:04:20 | Software Demonstration |
Saskia Fuhrmann (1,2), Wilhelm Huisinga (3) and Hans Peter Grimm (4) | Model-based comparison of mAb clearance in pediatric populations* | 2017 | 24-2-2017 9:47:10 | Poster: Drug/Disease modelling - Paediatrics |
Correlative analysis of response to treatment and biomarker levels in a setting with a time-to-event efficacy outcome and sparse biomarker data | 2017 | 24-2-2017 9:49:40 | Poster: Methodology - Other topics | |
Using repeated-time-to-event modelling and simulation of spontaneous bleeding events in the F8 KO rat model for informed decision making of study design | 2017 | 24-2-2017 10:00:17 | Poster: Drug/Disease modelling - Other topics | |
Pascal Schulthess (1), Teun Post (1,2), James Yates (3), and Piet Hein van der Graaf (1,4) | Frequency-domain response analysis for quantitative systems pharmacology models | 2017 | 24-2-2017 10:23:07 | Poster: Methodology - New Modelling Approaches |
Multiscale mechanistic models in Systems Pharmacology: development of a model describing Atorvastatin pharmacokinetics through integration of metabolic network in Physiologically Based Pharmacokinetic models. | 2017 | 24-2-2017 10:45:51 | Poster: Drug/Disease modelling - Absorption & PBPK | |
CHF5993 a triple combination therapy for COPD patients: population PK modelling of formoterol following pMDI inhalation | 2017 | 24-2-2017 11:29:05 | Poster: Drug/Disease modelling - Other topics | |
Construction and evaluation of "global" Micahelis-Menten reduced models | 2017 | 24-2-2017 11:29:51 | Poster: Methodology - New Modelling Approaches | |
Jane Knöchel (1,2), Charlotte Kloft (3), Wilhelm Huisinga (1) | A novel measure of importance of state variables for model reduction: results for the blood coagulation network | 2017 | 24-2-2017 11:33:31 | Poster: Methodology - Other topics |
Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease | 2017 | 24-2-2017 11:45:18 | Poster: Drug/Disease modelling - Other topics | |
Neel Deferm (1), Janneke Keemink (1), Peter de Witte (2), Pieter Annaert (1), Thomas Bouillon (1) | Modeling of telmisartan disposition in sandwich-cultured rat hepatocytes. Does cryopreservation change disposition kinetics? | 2017 | 24-2-2017 12:07:28 | Poster: Drug/Disease modelling - Other topics |
Order in patch absorption rates? | 2017 | 24-2-2017 13:12:02 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Solène Desmée (1), Jérémie Guedj (2), Christine Veyrat-Follet (3) and Emmanuelle Comets (1,2) | Mechanistic joint modelling for longitudinal PSA and survival data in advanced metastatic prostate cancer | 2017 | 24-2-2017 13:27:31 | Poster: Drug/Disease modelling - Oncology |
Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL | 2017 | 24-2-2017 13:40:22 | Poster: Drug/Disease modelling - Oncology | |
Florence Loingeville (1), Thu Thuy Nguyen (1), Marie-Karelle Rivière (1,2), and France Mentré (1) | Using Hamiltonian Monte-Carlo to design longitudinal count studies accounting for parameter and model uncertainties | 2017 | 24-2-2017 14:17:06 | Poster: Methodology - Study Design |
Modelling of Dexamethasone in Paediatric Leukaemia Patients using a Population Pharmacokinetic Approach | 2017 | 24-2-2017 14:35:38 | Poster: Drug/Disease modelling - Paediatrics | |
Christer Rimmler (1), Dagmar Horn (2), Christian Lanckohr (3), Sari Ceren (3), Georg Hempel (1) | Development of a PBPK model to predict the pharmacokinetics of cefuroxime during surgery | 2017 | 24-2-2017 14:36:14 | Poster: Drug/Disease modelling - Absorption & PBPK |
Dose-exposure-response model between an ATR inhibitor and peripheral monocytes | 2017 | 24-2-2017 14:48:34 | Poster: Drug/Disease modelling - Oncology | |
A Shiny App for the Probability of Technical Success of a New Molecular Entity in the Preclinical to Clinical Translational Phase | 2017 | 24-2-2017 14:52:37 | Poster: Methodology - Other topics | |
Dupilumab dose selection for a phase 3 study in asthma patients: pharmacokinetic/pharmacodynamic (PK/PD) modelling and clinical trial simulation | 2017 | 24-2-2017 15:03:29 | Poster: Drug/Disease modelling - Other topics | |
Núria Buil-Bruna, Alienor Berges, S. Y. Amy Cheung, Martin Johnson, Helen Tomkinson | Predicting myelosuppression from phase I data: Which model should we use? | 2017 | 24-2-2017 15:13:28 | Poster: Drug/Disease modelling - Oncology |
Development and performance of npde for the evaluation of time-to-event model | 2017 | 24-2-2017 15:14:07 | Poster: Methodology - Model Evaluation | |
Population pharmacokinetics of gentamycin in hospitalized ICU patients | 2017 | 24-2-2017 15:17:43 | Poster: Drug/Disease modelling - Infection | |
Population Pharmacokinetic Analysis of Compound A and Its Metabolite in Healthy Subjects and Patients with Diabetic Nephropathy | 2017 | 24-2-2017 15:18:16 | Poster: Drug/Disease modelling - Other topics | |
Population Pharmacokinetics of Micafungin in critically ill patients - evaluation of a fixed dose regimen | 2017 | 24-2-2017 15:41:47 | Poster: Drug/Disease modelling - Infection | |
Normalisation weight in a covariate function affects the relative standard error of clearance: an example with paediatric data | 2017 | 24-2-2017 15:42:39 | Poster: Drug/Disease modelling - Paediatrics | |
Elena Maria Tosca (1), Maurizio Rocchetti (2), Paolo Magni (1) | A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens | 2017 | 24-2-2017 15:56:00 | Poster: Drug/Disease modelling - Oncology |
Target-mediated drug disposition model for a bispecific antibody: development of full model and quasi-equilibrium like approximation | 2017 | 24-2-2017 16:39:53 | Poster: Methodology - New Modelling Approaches | |
Olivier J David (1), Mita M Thapar (2), Colm B Farrell (2), Etienne Pigeolet (1) | CNP520 Phase III dose selection support: Identifying the doses producing a desired reduction in CSF Aß-40 | 2017 | 24-2-2017 17:54:03 | Poster: Drug/Disease modelling - CNS |
P. André (1), P. Wahl (2, 3), F. Livio (1), T. Buclin (1), M. Guidi (1, 4) | Population pharmacokinetics of vancomycin delivered from active calcium sulfate bone graft substitute. | 2017 | 24-2-2017 18:06:52 | Poster: Drug/Disease modelling - Infection |
Dominik Lott (1,2), Jasper Dingemanse (1), Thorsten Lehr (2), Andreas Krause (1) | Tolerance modeling: effects of the selective S1P1 receptor modulator ponesimod on heart rate | 2017 | 24-2-2017 18:15:38 | Poster: Drug/Disease modelling - Safety |
Simon Buatois(1,2), Sebastian Ueckert(3), Nicolas Frey(1),Sylvie Retout(1), France Mentré(2) | Modelling approaches in dose finding clinical trial: Simulation-based study comparing predictive performances of model averaging and model selection. | 2017 | 24-2-2017 18:57:12 | Oral: Methodology - New Modelling Approaches |
Dimitris T. Maris (1), Dimitris G. Patsatzis (1) and Dimitris A. Goussis (1). | Asymptotic Analysis on a TMDD model: Control of the process | 2017 | 24-2-2017 19:11:48 | Poster: Drug/Disease modelling - Absorption & PBPK |
Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 | 2017 | 25-2-2017 1:25:59 | Poster: Drug/Disease modelling - CNS | |
Cheikh Diack, Dietmar Schwab, Norman Mazer, Vincent Buchheit, Valerie Cosson, Nicolas Frey | A model-based meta-marker to characterize the response to ranibizumab in wet AMD patients | 2017 | 25-2-2017 2:04:23 | Poster: Drug/Disease modelling - Other topics |
Christian Laveille (1), Nicolas Simon (2), Hanane Gheit (3), Florence Porte-Thomé (3) | Population pharmacokinetics of Rimeporide: a sodium-hydrogen exchanger (NHE-1) inhibitor for patients with Duchenne Muscular Dystrophy (DMD) | 2017 | 25-2-2017 7:43:43 | Poster: Drug/Disease modelling - Paediatrics |
Alexios G. Tsiligiannis, Maria Sfouni and Aris Dokoumetzidis | Optimization of a paediatric FDC tablet and dosing regimen for the first line treatment of tuberculosis. | 2017 | 25-2-2017 9:31:03 | Poster: Drug/Disease modelling - Paediatrics |
Kairui Feng1, Robert H. Leary1, Michael Dunlavey1, Amin Rostami-Hodjegan1,2 | Study and application of nonparametric and parametric population modeling for automatic subpopulation classification to CYP2D6 phenotype compounds and pediatric age groups | 2017 | 25-2-2017 12:08:49 | Poster: Methodology - New Modelling Approaches |
Elisa Borella (1), Sean Oosterholt (2), Paolo Magni (1), Oscar Della Pasqua (2) | Paediatric trial design optimization using prior knowledge in combination with modelling & simulations | 2017 | 25-2-2017 14:08:37 | Oral: Lewis Sheiner Student Session |
A population parmacokinetic analysis of fimasartan, a novel angiotensin-receptor antagonist, in healthy subjects and patients with hypertension | 2017 | 25-2-2017 15:26:42 | Poster: Drug/Disease modelling - Other topics | |
Physiologically-based Pharmacokinetic (PBPK) Modeling of Simvastatin Drug-Drug Interactions with Rifampin, Clarithromycin and Drug-Gene Interaction with ABCG2 | 2017 | 25-2-2017 15:44:41 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Balancing efficacy and reduction in renal function to optimize initial gentamicin dosing in children with cancer | 2017 | 25-2-2017 18:06:19 | Oral: Drug/Disease modelling | |
Inhibition of bile acids synthesis via fibroblast growth factor 19 (FGF19) through intestinal signaling: A population analysis | 2017 | 25-2-2017 20:00:27 | Poster: Methodology - Other topics | |
Application of Model-Based Adaptive Optimal Design to determine a recommended dosing regimen for combination therapy in oncology | 2017 | 25-2-2017 20:50:13 | Poster: Methodology - Study Design | |
PBPK modeling of propofol using the middle out approach | 2017 | 25-2-2017 22:56:08 | Oral: Drug/Disease modelling | |
Execution of complex Bayesian workflows with the DDMoRe Interoperability Framework: a case study in the diabetes area | 2017 | 26-2-2017 0:08:34 | Poster: Methodology - Other topics | |
Nikhil Pillai, Sorell L. Schwartz, Thang Ho, Aris Dokoumetzidis, Robert Bies, Immanuel Freedman | Estimating Nonlinear Dynamic Systems in Pharmacology using Chaos Synchronization | 2017 | 26-2-2017 3:45:31 | Poster: Methodology - Estimation Methods |
Population pharmacokinetic analysis of meropenem in Korean patients with acute infections | 2017 | 26-2-2017 7:34:35 | Poster: Drug/Disease modelling - Infection | |
Waroonrat Sukarnjanaset (1), Thitima Wattanavijitkul (1), Sutep Jarurattanasirikul (2) | Performance of FOCEI vs SAEM in simple population pharmacokinetic analysis of rich, medium and sparse data. | 2017 | 26-2-2017 9:59:04 | Poster: Methodology - Estimation Methods |
Efficient identification of the optimal dosing regimen with a nonparametric method | 2017 | 26-2-2017 11:46:23 | Poster: Methodology - Other topics | |
In silico modelling of chylomicron association to predict lymphatic absorption of small molecules | 2017 | 26-2-2017 13:24:23 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Comparison of FO – FOCE population parameter estimation methods in PhysPK 2.0 against NONMEM 7.3 | 2017 | 26-2-2017 14:25:41 | Poster: Methodology - Model Evaluation | |
Sulav Duwal (1), Vikram Sunkara (1,2), Laura Dickinson (3), Saye Khoo (3), Max von Kleist (1) | Multiscale, mechanistic pipeline to assess the prophylactic efficacy of anti- HIV compounds | 2017 | 26-2-2017 14:36:30 | Poster: Drug/Disease modelling - Infection |
Which data are necessary to build a WB-PBPK model that accurately predicts exposure in the lung? A case study using Ethambutol for tuberculosis treatment | 2017 | 26-2-2017 15:01:08 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Yun Kim, Su-jin Rhee, Kyung-Sang Yu, In-Jin Jang, Seung Hwan Lee | A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects | 2017 | 26-2-2017 15:06:26 | Poster: Drug/Disease modelling - Infection |
A semi-mechanistic model to characterize the pharmacokinetics of orally administered S-Ketamine in healthy human subjects | 2017 | 26-2-2017 15:39:17 | Poster: Drug/Disease modelling - CNS | |
Assessing the adequacy of a minimal PK sampling schedule for individual dose adjustment decisions in a proof of mechanism (PoM) study in a special population | 2017 | 26-2-2017 17:39:16 | Poster: Methodology - Study Design | |
A new approach in pediatric drug design: the development of a pediatric pig model. Part II: The maturation of hepatic cytochrome P450 enzymes using enzyme activity and proteomics | 2017 | 26-2-2017 18:17:00 | Poster: Drug/Disease modelling - Other topics | |
Quantitative modelling to assess target engagement and pharmacology in early clinical development of an anti-OSM humanised mAb | 2017 | 26-2-2017 19:29:51 | Poster: Drug/Disease modelling - Other topics | |
Koen Jolling (1), Massimo Cella (2), Fabrizia Mariotti (2), Christian Laveille (1,3) | CHF5993 a triple combination therapy for COPD patients: population pharmacokinetic modelling of beclometasone-17-monopropionate (B17MP) following pMDI inhalation. | 2017 | 26-2-2017 19:56:23 | Poster: Drug/Disease modelling - Other topics |
Salvatore D’Agate (1), Ignacio Cotillo Torrejon (2), Paul Healy (1) and Oscar Della Pasqua (1,3) | Model-based screening of compounds for the treatment of Chagas disease, a neglected tropical disease. | 2017 | 26-2-2017 21:00:13 | Oral: Other Topics |
S Cristea (1), EAM Calvier (1), A Rostami-Hodjegan (2,3), EHJ Krekels (1), CAJ Knibbe (1,4) | The impact of renal transporters on paediatric renal clearance | 2017 | 26-2-2017 21:20:22 | Poster: Drug/Disease modelling - Paediatrics |
Scaling renal function in neonates and infants to describe the pharmacodynamics of antibiotic nephrotoxicity | 2017 | 26-2-2017 21:46:59 | Oral: Paediatrics - Scaling of pharmacodynamics | |
Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. | 2017 | 26-2-2017 22:26:27 | Poster: Drug/Disease modelling - Oncology | |
Quantifying adaptive resistance in bacteria using well-designed dynamic time-kill curve experiments | 2017 | 26-2-2017 23:27:02 | Poster: Drug/Disease modelling - Infection | |
Antibiotic Efficacy during Spaceflight: Impact of Simulated Microgravity on Killing of S. pneumoniae by Ciprofloxacin | 2017 | 26-2-2017 23:58:55 | Poster: Drug/Disease modelling - Infection | |
Tofacitinib exposure-response modeling of partial Mayo score in ulcerative colitis patients in phase 3 induction studies | 2017 | 27-2-2017 2:12:24 | Poster: Drug/Disease modelling - Other topics | |
Sang-In Park (1), Jaeseong Oh (1), SeungHwan Lee (1), Kyung-Sang Yu (1) | Population pharmacokinetic analysis of evogliptin in subjects with varying degrees of renal function | 2017 | 27-2-2017 2:44:04 | Poster: Drug/Disease modelling - Other topics |
Yu Kyong Kim (1), Euitae Kim (2), Jae-Yong Chung (3), Seonghae Yoon (3) | Population Pharmacokinetic Model Development for Long-Acting Intramuscular Injection of Drug X in Healthy Subjects | 2017 | 27-2-2017 3:07:56 | Poster: Drug/Disease modelling - Other topics |
Development of a Semi-mechanistic absorption model for explaining effect of food on itraconazole | 2017 | 27-2-2017 3:31:53 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Population pharmacokinetic and time-to-event modelling of the antimalarial drug lumefantrine in young children with severe acute malnutrition | 2017 | 27-2-2017 4:34:07 | Poster: Drug/Disease modelling - Paediatrics | |
Correction of the likelihood function as an alternative for imputing missing covariates | 2017 | 27-2-2017 5:38:05 | Oral: Methodology - New Modelling Approaches | |
Population pharmacokinetics(PK)/Pharmacodynamics(PD) modeling and simulation of vancomycin in pediatric infectious patients | 2017 | 27-2-2017 6:36:09 | Poster: Drug/Disease modelling - Paediatrics | |
Population pharmacokinetic properties of piperaquine in falciparum malaria: An individual participant data meta-analysis | 2017 | 27-2-2017 6:48:41 | Poster: Drug/Disease modelling - Infection | |
Placental Transfer of Darunavir and Simulation of Fetal Exposure | 2017 | 27-2-2017 6:52:00 | Poster: Drug/Disease modelling - Paediatrics | |
Pharmacokinetic-pharmacodynamic modelling of artesunate in patients with drug resistant and sensitive malaria | 2017 | 27-2-2017 6:52:34 | Oral: Drug/Disease modelling | |
Nina Hanke (1), Sebastian Frechen (2), Thomas Eissing (2), Thomas Wendl (2) and Thorsten Lehr (1) | Physiologically-based pharmacokinetic (PBPK) modeling of alfentanil as a CYP3A4 victim drug | 2017 | 27-2-2017 7:13:18 | Poster: Drug/Disease modelling - Absorption & PBPK |
Anne Chain (1), Leila Kheibarshekan (2), Rebecca Wrishko (3), Nathalie H Gosselin (2) | An Extrapolation Approach to Aprepitant Pediatric Drug Development | 2017 | 27-2-2017 7:45:22 | Poster: Drug/Disease modelling - Paediatrics |
Therapeutic antibody concentrations at the biophase | 2017 | 27-2-2017 7:52:40 | Oral: Other Topics | |
Clémence Rigaux (1), Bernard Sébastien (1), Britta Goebel (2) | Pharmacokinetic/Pharmacodynamic Modelling of Recurrent Adverse Events as Function of Drug Concentration and Time | 2017 | 27-2-2017 8:25:22 | Poster: Drug/Disease modelling - Safety |
Jennifer Leohr(1), Michael Heathman(1), and Maria C. Kjellsson(2) | A Semi-Physiologic Model of Postprandial Triglyceride Response following Anti-Obesity Therapy | 2017 | 27-2-2017 8:50:34 | Poster: Drug/Disease modelling - Endocrine |
Pharmacokinetic modeling of Donepezil after transdermal administration in rat | 2017 | 27-2-2017 9:03:20 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Towards population physiology based pharmacokinetics modelling (popPBPK) in an industrial environment | 2017 | 27-2-2017 9:03:56 | Poster: Methodology - Estimation Methods | |
Application of Global Sensitivity Analysis Methods to Determine the most Influential Parameters of a Minimal PBPK Model of Quinidine | 2017 | 27-2-2017 9:10:15 | Poster: Methodology - Model Evaluation | |
Translational systems pharmacology for acquisition of knowledge and prediction of drug pharmacokinetics across patient populations | 2017 | 27-2-2017 9:25:16 | Oral: Clinical Applications | |
Population Pharmacokinetic Modeling of Simeprevir – Odalasvir Interaction in Healthy Volunteers | 2017 | 27-2-2017 9:38:13 | Poster: Drug/Disease modelling - Infection | |
Dose-saturable model for amoxicillin used to predict probability of response in normal and obese pediatrics | 2017 | 27-2-2017 9:47:05 | Poster: Drug/Disease modelling - Paediatrics | |
Population pharmacokinetic modelling of sustained-release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. | 2017 | 27-2-2017 10:01:35 | Poster: Drug/Disease modelling - Other topics | |
Placebo and drug response assessment on Unified Parkinson’s Disease Rating Scale using longitudinal Item Response Modelling | 2017 | 27-2-2017 10:04:34 | Poster: Drug/Disease modelling - CNS | |
Population pharmacokinetic-based interspecies allometric scaling and prediction of first-in-human (FIH) pharmacokinetics of a new anticancer agent | 2017 | 27-2-2017 10:07:34 | Poster: Drug/Disease modelling - Oncology | |
A model-based comparison of absorption pharmacokinetics for a selective glucocorticoid receptor modulator administered with different inhalation devices | 2017 | 27-2-2017 10:11:50 | Poster: Drug/Disease modelling - Other topics | |
Population Pharmacokinetics of Tacrolimus in Healhty Korean Subjects:role of CYP3A5 genotype and metabolite | 2017 | 27-2-2017 10:53:30 | Poster: Drug/Disease modelling - Other topics | |
Belén P.Solans (1, 2), Marta Santisteban (3), Iñaki F. Trocóniz (1, 2) | Modelling tumour growth and progression free survival of breast cancer patients treated with neoadjuvant therapy | 2017 | 27-2-2017 10:56:55 | Poster: Drug/Disease modelling - Oncology |
Population pharmacokinetics and cardiovascular safety of piperaquine in African patients with uncomplicated malaria | 2017 | 27-2-2017 11:17:48 | Poster: Drug/Disease modelling - Infection | |
dfpk: an R package for a practical implementation of PK measurements in dose-finding studies | 2017 | 27-2-2017 11:34:47 | Poster: Methodology - Other topics | |
Manoranjenni Chetty, Mailys De Sousa Mendes, Karen Rowland-Yeo | Prediction of the pharmacokinetics of renally excreted antiretrovirals in older patients, using physiologically based pharmacokinetic (PBPK) modelling. | 2017 | 27-2-2017 11:46:12 | Poster: Drug/Disease modelling - Absorption & PBPK |
Quantifying the growth hormone lowering effect of BIM23B065 after a GH stimulation test | 2017 | 27-2-2017 11:46:36 | Poster: Drug/Disease modelling - Endocrine | |
Comparison of pharmacokinetic parameters estimated by the experimental R package 'nlmixr' and MONOLIX | 2017 | 27-2-2017 11:51:37 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Evaluation of tumor kinetics metrics as early endpoint to support decision making in early drug development | 2017 | 27-2-2017 11:59:45 | Poster: Methodology - Study Design | |
Konstantina Soulele (1), Panos Macheras (1,2), Vangelis Karalis (1) | On the population pharmacokinetics and the enterohepatic recirculation of inhaled formoterol in asthma patients | 2017 | 27-2-2017 12:02:52 | Poster: Drug/Disease modelling - Absorption & PBPK |
Minimization of a utility function for optimizing the dosing frequency of amoxicillin administration in neonates according to a fixed PK/PD index | 2017 | 27-2-2017 12:03:11 | Poster: Drug/Disease modelling - Paediatrics | |
Andre Dallmann (1), Ibrahim Ince (2), Katrin Coboeken (2), Thomas Eissing (2), Georg Hempel (1) | Physiologically-based pharmacokinetic modeling of drugs metabolized via several CYP enzymes in populations of pregnant women | 2017 | 27-2-2017 12:03:31 | Poster: Drug/Disease modelling - Absorption & PBPK |
Joint modeling of overall survival and tumor size dynamics in non-small cell lung cancer: Clinical trial simulations and validation of predictions at study and subject levels | 2017 | 27-2-2017 12:11:43 | Oral: Methodology - New Modelling Approaches | |
Kernel-based visual hazard comparison (kbVHC): a simulation-free diagnostic for parametric repeated time-to-event models | 2017 | 27-2-2017 12:12:38 | Poster: Methodology - Model Evaluation | |
Effects of Formula Milk on Weight Changes in Healthy Term and Preterm Neonates | 2017 | 27-2-2017 12:14:00 | Poster: Drug/Disease modelling - Paediatrics | |
The role of modelling and simulation in the paediatric investigation plan of a xanthine oxidase inhibitor for tumor lysis syndrome prevention | 2017 | 27-2-2017 12:27:57 | Poster: Drug/Disease modelling - Paediatrics | |
Preclinical pharmacokinetic-pharmacodynamic modelling to guide first-time-in-human studies with the anti-miR-103/107, RG-125 (AZD4076) | 2017 | 27-2-2017 12:43:08 | Poster: Drug/Disease modelling - Other topics | |
Sunae Ryu(1), Sunny Park(1), Jong-Gu Lee(1), Ze-Won Park(1), Woo-Yong Oh(1), Seung-Eun Choi(1) | Population pharmacokinetic model of propranolol and its metabolite reflecting the first-pass effect in patients with hepatic impairment | 2017 | 27-2-2017 12:56:21 | Poster: Drug/Disease modelling - Other topics |
Drug targeting in pulmonary sub-epithelial compartments predicted through systems pharmacology modelling | 2017 | 27-2-2017 13:00:13 | Poster: Drug/Disease modelling - Absorption & PBPK | |
The Open Systems Pharmacology Suite (PK-Sim® & MoBi®): An open source solution for whole-body physiologically based pharmacokinetics and -dynamics | 2017 | 27-2-2017 13:04:42 | Poster: Methodology - Other topics | |
A parent-metabolite pharmacokinetic model of paracetamol in zebrafish | 2017 | 27-2-2017 13:08:24 | Poster: Drug/Disease modelling - Other topics | |
Linking rifampicin exposure to treatment response over 6 months in patients with pulmonary tuberculosis | 2017 | 27-2-2017 13:12:45 | Poster: Drug/Disease modelling - Infection | |
Pharmacokinetic and exposure-response analyses supporting ticagrelor dosing recommendation in patients with prior myocardial infarction (PEGASUS-TIMI 54) | 2017 | 27-2-2017 13:13:07 | Poster: Drug/Disease modelling - Other topics | |
Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients | 2017 | 27-2-2017 13:14:43 | Poster: Drug/Disease modelling - Other topics | |
Investigation of Bayesian inference in predicting tissue concentrations using RStan | 2017 | 27-2-2017 13:25:46 | Poster: Methodology - New Modelling Approaches | |
Quantification of Anti-Drug-Antibodies (ADA) Impact on Drug Exposure Using a Population PK modeling Approach | 2017 | 27-2-2017 13:33:20 | Poster: Drug/Disease modelling - Other topics | |
Conceptual evaluation of urea rebound in pediatric hemodialysis patients by a physiology-based pharmacokinetic simulation study | 2017 | 27-2-2017 13:35:25 | Poster: Drug/Disease modelling - Paediatrics | |
Evaluation of immediate release exenatide effects on gastric motility and intestinal glucose absorption using a systems pharmacology model | 2017 | 27-2-2017 13:57:26 | Poster: Drug/Disease modelling - Endocrine | |
Tigecycline population pharmacokinetics in patients with severe sepsis or septic shock resulting from abdominal surgery | 2017 | 27-2-2017 14:03:39 | Poster: Drug/Disease modelling - Infection | |
A systems pharmacology approach unravels the dynamics of the APP pathway and unfolds Aß oligomer modulation | 2017 | 27-2-2017 14:23:17 | Poster: Drug/Disease modelling - CNS | |
Model-based rationale for drug combinations in tuberculosis | 2017 | 27-2-2017 14:26:11 | Oral: Lewis Sheiner Student Session | |
CHF5993 a triple combination therapy for COPD patients: population PK modelling of glycopyrronium bromide (GB) following pMDI inhalation. | 2017 | 27-2-2017 14:35:18 | Poster: Drug/Disease modelling - Other topics | |
Nathalie Perdaems (1), Sylvain Fouliard (1), Marylore Chenel (1) | Multi-species translational PK/PD modelling in type 2 diabetes | 2017 | 27-2-2017 14:39:26 | Poster: Drug/Disease modelling - Endocrine |
Operating Characteristics of Stepwise Covariate Selection in Pharmacometric Modeling | 2017 | 27-2-2017 14:39:39 | Poster: Methodology - Covariate/Variability Models | |
Moustafa M.A. Ibrahim (1), Rikard Nordgren (1), Maria C. Kjellsson (1), Mats O. Karlsson (1) | Model-based diagnostics post-processing for fast automated model building; show-cased with residual error models and CWRES. | 2017 | 27-2-2017 14:52:33 | Poster: Methodology - Estimation Methods |
Donato Teutonico (1), Maud Beneton (1), Magali Amiel (1), Marylore Chenel (1) | Development of a PBPK model to describe late colonic absorption after oral administration | 2017 | 27-2-2017 14:56:27 | Poster: Drug/Disease modelling - Absorption & PBPK |
Examining the relationship between paclitaxel exposure and peripheral neuropathy in non-small cell lung cancer | 2017 | 27-2-2017 15:10:40 | Poster: Drug/Disease modelling - Oncology | |
Vincent CROIXMARIE (1), Sophie PEIGNE (1), Donato TEUTONICO (1) and Marylore CHENEL (1) | DDMoRe private repository linked with an in-house PK database | 2017 | 27-2-2017 15:11:57 | Poster: Methodology - Other topics |
Rocio Lledo-Garcia (1), Grant Langdon (1,2), Ruth Oliver (1) | PK/PD modelling of an anti-FcRn mAb to optimise FIM design - translation from cyno to human | 2017 | 27-2-2017 15:22:02 | Poster: Drug/Disease modelling - Other topics |
How to handle non-linearity in absorption: a case study in oncology | 2017 | 27-2-2017 15:22:25 | Poster: Drug/Disease modelling - Oncology | |
Gilbert Koch (1), Marc Pfister (1), Kerstin Jost (2), Alexandre N. Datta (3) | Characterization of heart rate and sleeping patterns in pre-term neonates | 2017 | 27-2-2017 15:24:44 | Poster: Drug/Disease modelling - Paediatrics |
Christine Xu (1), Yaming Su (2), Anne Paccaly (3), Vanaja Kanamaluru (1) | Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis | 2017 | 27-2-2017 15:27:48 | Poster: Drug/Disease modelling - Other topics |
Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA) after single-dose administration | 2017 | 27-2-2017 15:37:13 | Poster: Drug/Disease modelling - Safety | |
Exposure/Response modeling for sarilumab dose regimens benefit/risk assessment | 2017 | 27-2-2017 15:42:44 | Poster: Drug/Disease modelling - Other topics | |
Exposure response relationship for interstitial lung disease (ILD) events following osimertinib treatment | 2017 | 27-2-2017 15:51:43 | Poster: Drug/Disease modelling - Oncology | |
Yuri Kheifetz; Prof. Dr. Markus Scholz; Prof. Dr. Markus Loeffler | Model-based individual managing of thrombocytopenia during multi-cyclic chemotherapy | 2017 | 27-2-2017 16:10:10 | Oral: Drug/Disease modelling |
Lénaïg Tanneau (1), Mats O Karlsson (1), Elin M Svensson (1,2) | Bedaquiline’s exposure-response relationship evaluated with data from the observational study C209 | 2017 | 27-2-2017 16:12:28 | Poster: Drug/Disease modelling - Infection |
João A. Abrantes (1), Siv Jönsson (1), Mats O. Karlsson (1), Elisabet I. Nielsen (1) | Handling inter-occasion variability in model-based therapeutic drug monitoring | 2017 | 27-2-2017 16:13:42 | Poster: Methodology - Covariate/Variability Models |
Circadian quantitative system pharmacology model to inform clinical study design and translation to human | 2017 | 27-2-2017 16:17:17 | Poster: Drug/Disease modelling - CNS | |
Gustaf J Wellhagen (1), Tore Bjerregaard Stage (1,2,3), Kim Brøsen (2), Maria C Kjellsson (1) | Impact of genotype assumption in a semi-mechanistic PK model of metformin | 2017 | 27-2-2017 16:25:24 | Poster: Drug/Disease modelling - Endocrine |
Varenicline exposure is associated with abstinence from smoking in a cohort of smokers from the general population | 2017 | 27-2-2017 16:32:57 | Poster: Drug/Disease modelling - Other topics | |
Longitudinal Model-Based Meta-Analysis (MBMA) for rheumatoid arthritis with Monolix | 2017 | 27-2-2017 16:33:34 | Poster: Methodology - New Modelling Approaches | |
Lopinavir/Ritonavir Super-boosting Overcomes Interactions In Children Treated With Rifampicin: A Model-Based Approach For Non-Inferiority Trials | 2017 | 27-2-2017 16:33:50 | Poster: Drug/Disease modelling - Infection | |
Mechanism-Based Modeling In Chronic Heptatis B | 2017 | 27-2-2017 16:37:42 | Poster: Drug/Disease modelling - Infection | |
Geraldine Ayral (1), Kaelig Chatel (1), Marc Lavielle (2)(3), Jonathan Chauvin (1) | Tobramycin dose individualization using the MonolixSuite | 2017 | 27-2-2017 16:38:15 | Poster: Methodology - New Modelling Approaches |
Population pharmacokinetic model of mitotane enzyme autoinduction in adrenocortical carcinoma patients | 2017 | 27-2-2017 16:39:25 | Poster: Drug/Disease modelling - Oncology | |
Validation of a Network Systems Pharmacology model for Inflammatory Bowel | 2017 | 27-2-2017 16:48:08 | Poster: Drug/Disease modelling - Other topics | |
Target-mediated drug-disposition (TMDD) model comparison using the MonolixSuite | 2017 | 27-2-2017 16:50:20 | Poster: Methodology - New Modelling Approaches | |
A Comprehensive Model-Based Meta-Analysis (MBMA) of Diabetes Studies in Type 2 Diabetes Mellitus Patients to Quantify the Relationship between HbA1c and Fasting Plasma Glucose | 2017 | 27-2-2017 16:52:01 | Poster: Drug/Disease modelling - Endocrine | |
Sami Ullah (1), Peter Matzneller (2), Markus Zeitlinger (2), Uwe Fuhr (1), Max Taubert (1) | Population pharmacokinetic analysis of intravenous telavancin in healthy subjects undergoing plasma and tissue microdialysis | 2017 | 27-2-2017 17:07:29 | Poster: Drug/Disease modelling - Infection |
Pharmacokinetic/pharmacodynamic modeling of anidulafungin time-kill curves against Candida considering antifungal resistance | 2017 | 27-2-2017 17:07:43 | Poster: Drug/Disease modelling - Infection | |
Ajit Suri (1), Diane Mould (2), Graham Jang (3), Dirk Huebner (1) and Karthik Venkatakrishnan (1) | Population Pharmacokinetic Modeling of Brentuximab Vedotin, a CD30-Directed Antibody-Drug Conjugate, and its cytotoxic payload (MMAE) in Patients With Various Hematological Malignancies | 2017 | 27-2-2017 17:21:04 | Poster: Drug/Disease modelling - Oncology |
Influence of nevirapine and ritonavir/lopinavir based antiretroviral therapy on Lumefantrine exposure in HIV-1 infected patients. | 2017 | 27-2-2017 17:25:37 | Poster: Drug/Disease modelling - Infection | |
PBPK versus PK modeling of Tacrolimus drug in patients with renal transplant as knowledge engines for personalized posology software: PhysPK® development and preliminary results | 2017 | 27-2-2017 17:37:00 | Poster: Drug/Disease modelling - Other topics | |
Model-Informed Drug Development (MIDD) for ixazomib, an oral proteasome inhibitor | 2017 | 27-2-2017 17:37:55 | Oral: Benefit-Risk assessment | |
Population Pharmacokinetics of Abacavir in HIV-infected African children | 2017 | 27-2-2017 17:40:16 | Poster: Drug/Disease modelling - Paediatrics | |
A semi-physiological model for moxifloxacin pharmacokinetics which includes the effect of co-administered drugs and genetic polymorphisms | 2017 | 27-2-2017 17:41:24 | Poster: Drug/Disease modelling - Other topics | |
Population Pharmacokinetics of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria. | 2017 | 27-2-2017 17:41:41 | Poster: Drug/Disease modelling - Infection | |
DDEXPAND interface for coding delay differential equations based models in NONMEM | 2017 | 27-2-2017 17:49:37 | Software Demonstration | |
A Bayesian approach for population pharmacokinetic modeling of alcohol in Japanese Subjects | 2017 | 27-2-2017 17:53:37 | Poster: Drug/Disease modelling - CNS | |
Exploring and explaining variability in tamoxifen and endoxifen pharmacokinetics in breast cancer patients: A pooled analysis | 2017 | 27-2-2017 18:08:03 | Poster: Drug/Disease modelling - Oncology | |
Towards understanding the loss of response to infliximab in patients with inflammatory bowel disease: A population PK modelling approach | 2017 | 27-2-2017 18:12:53 | Poster: Drug/Disease modelling - Other topics | |
Modelling body mass index trajectory in HIV-infected individuals | 2017 | 27-2-2017 18:13:19 | Poster: Drug/Disease modelling - Infection | |
Emma C. Martin (1), Leon Aarons (1), Hitesh Mistry (1), James W.T. Yates (2) | Using mixed effects modelling improves detection of drug-gene interactions in mouse trials | 2017 | 27-2-2017 18:16:20 | Poster: Drug/Disease modelling - Oncology |
S.E. Berends(1,2), T.J. van Steeg(3), M.J. Ahsman(3), G.R.A.M. D’Haens(2), R.A.A. Mathôt(1) | A Target-Mediated Drug Disposition model for infliximab in patients with Ulcerative Colitis | 2017 | 27-2-2017 18:16:20 | Poster: Drug/Disease modelling - Other topics |
Handling frequent observations of composite scores: Application to PROs in COPD | 2017 | 27-2-2017 18:16:29 | Oral: Methodology - New Modelling Approaches | |
Model based predictions of the PTG-100 pharmacodynamic responses in ulcerative colitis patients | 2017 | 27-2-2017 18:22:55 | Poster: Drug/Disease modelling - Other topics | |
Population pharmacokinetics of unbound voriconazole following two different routes of administration during sequence therapy | 2017 | 27-2-2017 18:28:29 | Poster: Drug/Disease modelling - Infection | |
Is a pooled population pharmacokinetic model predictive of plasma and microdialysate pharmacokinetics of linezolid in obese and non-obese patients? | 2017 | 27-2-2017 18:38:05 | Poster: Drug/Disease modelling - Infection | |
Pharmacodynamics of vancomycin in children | 2017 | 27-2-2017 18:42:23 | Poster: Drug/Disease modelling - Paediatrics | |
The purpose determines the predictive performance: Comparison of four population pharmacokinetic models of methotrexate. | 2017 | 27-2-2017 18:50:12 | Poster: Drug/Disease modelling - Oncology | |
A model of insulin kinetics describing tests with various insulin secretion and infusion patterns by means of a consistent mechanism | 2017 | 27-2-2017 18:59:54 | Poster: Drug/Disease modelling - Endocrine | |
Nadia Terranova (1), Christine Hicking (2), Fernando Dangond (3), Alain Munafo (1) | Simulation analysis of absolute lymphocytes counts (ALC) and relapse rate (RR) following cladribine (re-)treatment rules in subjects with relapsing-remitting multiple sclerosis (RRMS) | 2017 | 27-2-2017 19:00:52 | Oral: Benefit-Risk assessment |
An Immune quantitative network aimed for viral hepatitis B | 2017 | 27-2-2017 19:05:22 | Poster: Drug/Disease modelling - Infection | |
Impact of rise in anti-drug antibodies on the pharmacokinetics of the monoclonal antibody adalimumab | 2017 | 27-2-2017 19:14:09 | Poster: Drug/Disease modelling - Other topics | |
Herceptin in HER2-positive Gastric Cancer: Evaluation of Exposure-Response with Two Dose Levels. | 2017 | 27-2-2017 19:14:40 | Poster: Drug/Disease modelling - Oncology | |
Ana M Novakovic (1), Sebastian Ueckert (1), Alain Munafo (2), Mats O Karlsson (1) | A longitudinal model linking absolute lymphocyte count (ALC) and volume of T2 lesions to expanded disability status scale (EDSS) in patients with relapsing-remitting multiple sclerosis (RRMS) | 2017 | 27-2-2017 19:14:55 | Poster: Drug/Disease modelling - CNS |
Simulo – a platform for advanced model based simulations using R | 2017 | 27-2-2017 19:17:09 | Software Demonstration | |
Host-Pathogen interactions: A mechanism-based disease progression model to describe the pathogenesis of Acinetobacter baumannii pneumonia | 2017 | 27-2-2017 19:18:43 | Oral: Lewis Sheiner Student Session | |
A Novel Mechanism-Based Pharmacokinetic-Pharmacodynamic Model Describing Ceftazidime-Avibactam (CAZ-AVI) Efficacy Against β-lactamase-Producing Klebsiella pneumoniae and Pseudomonas aeruginosa Isolates | 2017 | 27-2-2017 19:19:29 | Poster: Drug/Disease modelling - Infection | |
Tigecycline-Tetracycline Combination Modeling against Pseudomonas aeruginosa: Application of the General Pharmacodynamic Interaction Term in Various Interaction Models | 2017 | 27-2-2017 19:48:04 | Poster: Drug/Disease modelling - Infection | |
Population PD modelling of circulating biomarkers in patients with melanoma treated with interferon alpha2b | 2017 | 27-2-2017 19:52:42 | Poster: Drug/Disease modelling - Oncology | |
Tsiros Periklis (1), Tsiliki Georgia (1), Dokoumetzidis Aristeidis (2), Sarimveis Haralambos(1) | Bayesian Whole Body Population Physiologically Based Pharmacokinetic Approach for Characterization of Interindividual Variability of Diazepam | 2017 | 27-2-2017 20:11:21 | Poster: Drug/Disease modelling - Absorption & PBPK |
Radiation and anti-PD-L1 treatment combinations: Immune cell responses and dose scheduling optimization using a joint experimental and systems modeling approach | 2017 | 27-2-2017 20:14:50 | Poster: Drug/Disease modelling - Oncology | |
High exposure to fludarabine in conditioning prior to allogeneic hematopoietic cell transplantation predicts impaired CD4 reconstitution and lower probability of survival | 2017 | 27-2-2017 20:17:27 | Oral: Drug/Disease modelling | |
Richard Dimelow, Chiara Zecchin, Stefano Zamuner, Monica Simeoni | Effect of dataset characteristics on estimation method performance: a TMDD model example | 2017 | 27-2-2017 20:23:33 | Poster: Methodology - Estimation Methods |
Using pharmacokinetic simulation to guide dose escalation decisions for targeted IL2v immunocytokines | 2017 | 27-2-2017 20:25:45 | Oral: Clinical Applications | |
Population pharmacokinetic of tamoxifen and its metabolites in breast cancer patients | 2017 | 27-2-2017 20:34:24 | Poster: Drug/Disease modelling - Oncology | |
A Mechanism-Based Model of Tumor Quiescence and Resistance in HER2-Negative Metastatic Breast Cancer in Patients Receiving Docetaxel or Paclitaxel | 2017 | 27-2-2017 20:35:18 | Poster: Drug/Disease modelling - Oncology | |
Henrik Bjugård Nyberg[1], Andrew C. Hooker[1], Robert J. Bauer[2], Yasunori Aoki[3] | SADDLE_RESET: more robust parameter estimation with a check for local practical identifiability | 2017 | 27-2-2017 20:47:55 | Oral: Methodology - New Tools |
PharmTeX: a LaTeX-based open-source platform for automated reporting workflow | 2017 | 27-2-2017 20:51:38 | Poster: Methodology - Other topics | |
Sensitivity analysis of P-glycoprotein Ki values in dynamic DDI predictions | 2017 | 27-2-2017 20:52:37 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Victor Mangas Sanjuan (1,2), Elba Romero (3), Iñaki F Troconiz (1) | Semi-mechanistic Pharmacodynamic model of complex receptor-hormone dynamics | 2017 | 27-2-2017 21:08:09 | Poster: Methodology - New Modelling Approaches |
Souvik Bhattacharya (1), Timothy Nicholas (2), Lawrence J. Lesko (1), Mirjam N. Trame (1) | Longitudinal Parkinson’s Disease Progression Model using Item-Response-Theory Utilized to Predict Treatment Effect of Levodopa | 2017 | 27-2-2017 21:10:27 | Poster: Drug/Disease modelling - CNS |
Power calculation methods to detect covariates effect when combining observed and simulated data. | 2017 | 27-2-2017 21:12:21 | Poster: Methodology - Study Design | |
Population PK Modeling of Dapivirine released from Vaginal Rings | 2017 | 27-2-2017 21:16:30 | Poster: Drug/Disease modelling - Other topics | |
Optimising Phase 1 oncology dosing schedule of an ATR inhibitor in real time using a model informed approach to predict myelosuppression | 2017 | 27-2-2017 21:18:06 | Poster: Drug/Disease modelling - Oncology | |
Influence of the number of tumor size measurements on model-derived tumor size metrics and prediction of survival | 2017 | 27-2-2017 21:22:15 | Poster: Drug/Disease modelling - Oncology | |
Joint pharmacogenetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients | 2017 | 27-2-2017 21:52:27 | Poster: Drug/Disease modelling - Infection | |
Population pharmacokinetic model for levodopa/carbidopa microtablets in Parkinson’s disease patients and healthy subjects | 2017 | 27-2-2017 21:57:04 | Poster: Drug/Disease modelling - CNS | |
Nikhil S Pillai (1), Eric A. Sherer (2), Mark Sale (3). Rob Bies (1) | Application of global search methods for parameter estimation in models with poorly defined objective function surfaces | 2017 | 27-2-2017 22:03:26 | Poster: Methodology - Estimation Methods |
Sahota, Tarjinder (1), Ruau, David (2), Fox, Robert (3), Al-Huniti, Nidal (3) | NMproject: Tidy, Reproducible, Script Based NONMEM projects in RStudio. A Step Toward Pharmacometric Industrialisation. | 2017 | 27-2-2017 22:32:52 | Software Demonstration |
Impact of metabolic polymorphism on the exposure to tramadol and its active metabolite in children | 2017 | 27-2-2017 22:43:17 | Poster: Drug/Disease modelling - Paediatrics | |
Shafi Chowdhury (1), Rajwanur Rahman (2), Kantish Chowdhury (2) | Using “Big” NONMEM Dataset Generated from Standard SDTM to Review Data and Accelerate Model Building Process | 2017 | 27-2-2017 22:47:07 | Poster: Methodology - New Modelling Approaches |
A comparison of performance between parametric and nonparametric estimation for nonlinear mixed-effects models | 2017 | 27-2-2017 22:47:11 | Oral: Non-standard estimation methods | |
Model Simplification | 2017 | 27-2-2017 22:50:56 | Poster: Methodology - Model Evaluation | |
Modeling of Interferon effector pathway after viral infection | 2017 | 27-2-2017 23:07:11 | Poster: Drug/Disease modelling - Infection | |
Solving linear ODEs using Krylov subspace projection methods | 2017 | 27-2-2017 23:14:43 | Poster: Methodology - Other topics | |
Ruben Faelens, Philippe Jacqmin, Per Olsson Gisleskog, Andreas Lindauer, Daniel Roeshammar | Clinical trial optimization of efficacy studies in slowly progressive diseases | 2017 | 27-2-2017 23:32:10 | Poster: Methodology - Study Design |
Gunnar Yngman (1,2), Joakim Nyberg (1), E. Niclas Jonsson (1) and Mats O. Karlsson (2) | Practical considerations for using the full random effects modeling (FREM) approach to covariate modeling | 2017 | 27-2-2017 23:39:35 | Poster: Methodology - Covariate/Variability Models |
Population PK and exposure-response analysis of sleep parameters for JNJ-42847922, a novel Orexin 2 receptor antagonist | 2017 | 27-2-2017 23:40:54 | Poster: Drug/Disease modelling - CNS | |
Dose-conversion factors for risperidone and paliperidone formulations based on steady-state PK similarity | 2017 | 27-2-2017 23:46:04 | Poster: Drug/Disease modelling - CNS | |
Maria Garcia-Cremades (1), Nicola Melillo (2), Paolo Magni (2), Iñaki F Troconiz (1) | Mechanistic multi-scale systems pharmacokinetics model applied for the anticancer drug gemcitabine in pancreatic cancer | 2017 | 27-2-2017 23:53:57 | Poster: Drug/Disease modelling - Oncology |
Statistical Power Analysis to Detect Drug-Drug Interaction between Lorezapam and Probenecid in Healthy and Renal-impaired Populations Using PBPK Modelling and the Simcyp R Package | 2017 | 27-2-2017 23:58:25 | Poster: Methodology - Study Design | |
Janak Wedagedera, Theresa Cain, Shriram Pathak, Masoud Jamei | Virtual Bioequivalence Assessment of Two Tramadol Formulations using the Advanced Dissolution Absorption and Metabolism (ADAM) model via Simcyp R Package | 2017 | 28-2-2017 0:04:28 | Poster: Drug/Disease modelling - Absorption & PBPK |
Sean Oosterholt (1), Anna Lisa Scardovi (2), Roberto Tonelli (3), Oscar Della Pasqua (1) | PKPD modelling of MYCN-inhibition in vitro and in vivo in a mouse model of neuroblastoma | 2017 | 28-2-2017 0:37:46 | Poster: Drug/Disease modelling - Oncology |
Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 | 2017 | 28-2-2017 0:40:38 | Poster: Drug/Disease modelling - CNS | |
Kayode Ogungbenro (1), Ivan Nestorov (2) and Srividya Neelakantan (3) | Sparse sampling design for characterizing individual PK of recombinant factor VIII fusion protein (rFVIIIFc) in prophylactic treatment of Hemophilia A | 2017 | 28-2-2017 2:18:51 | Poster: Methodology - Study Design |
Srividya Neelakantan (1), Lei Diao (2), and Ivan Nestorov (3) | Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects with Severe Hemophilia A Across All Ages | 2017 | 28-2-2017 3:05:30 | Poster: Drug/Disease modelling - Other topics |
Informing modeling and clinical trial simulation using the real world data: data content, quality and availability assessment | 2017 | 28-2-2017 3:09:43 | Poster: Methodology - Other topics | |
Tatiana Khariton (1), Joannellyn Chiu (1), Cara Cassino (2), Parviz Ghahramani (1) | Human Population PK Model, Dose Selection and Target Attainment Simulations for CF-301 - a Novel Antibacterial Lysin | 2017 | 28-2-2017 3:10:57 | Poster: Drug/Disease modelling - Infection |
Pre-clinical Population PK Model of CF-301 - a Novel Antibacterial Lysin | 2017 | 28-2-2017 3:34:34 | Poster: Drug/Disease modelling - Infection | |
Antimicrobial Drug Development Common Practices in PK-PD Model Selection and Common Misconceptions | 2017 | 28-2-2017 6:27:49 | Poster: Drug/Disease modelling - Infection | |
Ari Brekkan (1), Mats O. Karlsson (1), Siv Jönsson (1), Elodie L. Plan (1) | Parameter Estimation in Bivariate Mixed Hidden Markov Models | 2017 | 28-2-2017 7:56:44 | Poster: Methodology - New Modelling Approaches |
Extension of a pregnancy physiologically-based pharmacokinetic model for renally cleared drugs to the postpartum period | 2017 | 28-2-2017 8:56:39 | Poster: Drug/Disease modelling - Absorption & PBPK | |
Translational in-vitro in-vivo model to correlate HIPS derived cardiomyocyte contractility assay and in-vivo dog telemetry based dPdtmax measurements | 2017 | 28-2-2017 13:06:28 | Poster: Drug/Disease modelling - Safety | |
1,2Christophe Passot, 3Theo Rispens, 1,2Gilles Paintaud , 1,4Denis Mulleman, 1,2David Ternant | In-depth assessment of the influence of anti-drug antibodies on adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis | 2017 | 28-2-2017 16:37:43 | Poster: Drug/Disease modelling - Other topics |
An overview of non-parametric estimation methods used in population analysis | 2017 | 8-3-2017 16:41:58 | Oral: Tutorial | |
A model-based approach to extrapolate drug-drug interactions from rats to humans | 2017 | 20-3-2017 10:33:04 | Poster: Drug/Disease modelling - Other topics | |
Translational model-based approach to assist the dose-range selection of an antibody-drug conjugate entering Phase I | 2017 | 20-3-2017 12:16:23 | Poster: Drug/Disease modelling - Other topics | |
A clinical trial simulation study to investigate and compare efficacy and toxicity findings in parallel and titration designs | 2017 | 20-3-2017 13:36:58 | Poster: Methodology - Study Design | |
Sarah Siederer1, Shuying Yang2, Kimberley Hacquoil3, Kelly M. Mahar4 Misba Beerahee1 | Model Based Extrapolation Approach Driving a Streamlined Clinical Development Plan for Inhaled Oxytocin | 2017 | 21-3-2017 16:00:43 | Poster: Drug/Disease modelling - Other topics |
Predicting diclofenac systemic and synovial fluid concentrations after dermal application using the Multi-Phase Multi-Layer MechDermA PBPK model | 2017 | 22-3-2017 10:10:13 | Poster: Drug/Disease modelling - Absorption & PBPK | |
A Whole body Physiologically based Pharmacokinetic Model for Antibody drug conjugates - model development and validation in rat | 2017 | 28-3-2017 14:06:14 | Poster: Drug/Disease modelling - Absorption & PBPK | |
The new draft EMA Guidance on PBPK – The qualification of the intended use concept | 2017 | 29-3-2017 11:35:15 | Oral: Other Topics | |
Accuracy of plasma clearance scaling from adults to children using pathway-specific covariate models: a systematic investigation using a physiologically-based pharmacokinetic workflow | 2017 | 31-3-2017 8:09:49 | Poster: Drug/Disease modelling - Paediatrics | |
Scaling pharmacodynamics in children: Lessons from immunology, infectious diseases and critical care | 2017 | 3-4-2017 9:44:41 | Oral: Paediatrics - Scaling of pharmacodynamics | |
Regulatory pharmacometrics in the EU in practice and the role of the Modelling and Simulation Working Group | 2017 | 4-4-2017 11:45:39 | Oral: Other Topics | |
Registration at the conference venue | 2017 | 10-4-2017 11:17:51 | ||
Opening ceremony, welcome reception and dinner | 2017 | 10-4-2017 11:20:17 | ||
Registration at the conference venue | 2017 | 10-4-2017 11:20:51 | ||
Welcome and Introduction | 2017 | 10-4-2017 11:21:25 | ||
Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter | 2017 | 10-4-2017 11:22:08 | ||
Lunch | 2017 | 10-4-2017 11:22:42 | ||
Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter | 2017 | 10-4-2017 11:23:13 | ||
Presentation of Lewis Sheiner student session awards | 2017 | 10-4-2017 11:23:54 | ||
Lunch | 2017 | 10-4-2017 11:28:43 | ||
Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter | 2017 | 10-4-2017 11:29:16 | ||
Social event | 2017 | 10-4-2017 11:30:19 | ||
Preview of PAGE2018 | 2017 | 10-4-2017 11:30:51 | ||
Coffee break | 2017 | 10-4-2017 11:31:22 | ||
Closing remarks | 2017 | 10-4-2017 11:31:53 | ||
Audience input for potential PAGE2018 topics | 2017 | 10-4-2017 11:32:21 | ||
Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter | 2017 | 10-4-2017 11:41:41 | ||
Announcement for WCoP 2020 | 2017 | 10-4-2017 11:43:41 | ||
Announcement of ACoP8 | 2017 | 11-4-2017 14:53:37 | ||
Current practices and gaps in benefit-risk assessment: opportunities for combining MCDA with model-based approaches | 2017 | 24-4-2017 9:09:03 | Oral: Benefit-Risk assessment | |
Overview and implementation of multi criteria decision analysis (MCDA) for benefit-risk assessment | 2017 | 30-4-2017 15:03:23 | Oral: Benefit-Risk assessment | |
European regulatory views on benefit-risk assessment methodologies - role of MCDA and other model-based approaches | 2017 | 1-5-2017 15:14:08 | Oral: Benefit-Risk assessment | |
In memoriam Matt Hutmacher | 2017 | 9-5-2017 15:22:42 |
